We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Share :
Sorry, this item is currently unavailable.
Published: 5 Oct 2016
Views: 1648
Rating:
Save
Prof Gordon McVie - King's College London, London, UK

Prof McVie presents us with the arguments against using PDL1 and other biomarkers for selecting patients for immune checkpoint therapies, during the Controversies in NSCLC session at the Future Horizons in Lung Cancer meeting.